Eirion Therapeutics Announces Strategic Agreement

As part of the agreement, HTL will build, validate and operate a botulinum manufacturing facility in the US. In the future, HTL Biotechnology expects to apply to the CDC to have the facility certified to manufacture botulinum and later apply to the FDA to have it certified as a GMP plant.

Read more below.

English

French